Anixa Biosciences Inc represents a strong commitment to advanced cancer diagnostics and therapeutics. The company's corporate philosophy revolves around leveraging groundbreaking technologies and innovative approaches to improving patient outcomes in the field of oncology. Anixa believes in the power of precision medicine, striving to develop and commercialize highly accurate and personalized diagnostic tests that can detect cancers at early stages, allowing for more effective treatments. By harnessing the potential of artificial intelligence and bioinformatics, Anixa is dedicated to revolutionizing cancer care and enhancing the quality of life for cancer patients worldwide.

Anixa Biosciences Inc primarily operates in the United States.

Anixa Biosciences Inc has achieved significant milestones in its journey. The company has made notable advancements in the field of biosciences, contributing to groundbreaking research and development. With its unwavering commitment to innovation, Anixa Biosciences Inc has successfully launched several cutting-edge products and services. Additionally, the company has received recognition for its remarkable achievements, including prestigious awards and accolades within the industry. These milestones speak volumes about Anixa Biosciences Inc's dedication to pushing the boundaries of scientific exploration and its continued commitment to driving advancements in the biosciences sector.

Anixa Biosciences Inc. is a biotechnology company based in the United States. Founded in 1982, the company has a rich history of innovation and breakthroughs in the field of cancer diagnostics and therapeutics. With a strong focus on cutting-edge technologies, Anixa Biosciences has developed proprietary platforms and systems to detect and treat cancer at an early stage. The company has been involved in numerous research collaborations with leading academic institutions, further strengthening its position as a leader in the biotech industry. With a dedicated team of scientists and experts, Anixa Biosciences continues to make significant strides in improving cancer detection and treatment for the benefit of patients worldwide.

The main competitors of Anixa Biosciences Inc in the market include companies such as Guardant Health, Exact Sciences Corporation, and Foundation Medicine. These companies are also engaged in molecular diagnostics and cancer testing, providing innovative solutions for early detection and personalized medicine. However, Anixa Biosciences sets itself apart through unique technology platforms and partnership collaborations to develop cutting-edge diagnostics and therapeutic treatments in various areas, including liquid biopsy, artificial intelligence, and immuno-oncology.

Anixa Biosciences Inc is primarily active in the biotechnology and healthcare industries.

The business model of Anixa Biosciences Inc is focused on developing and commercializing innovative diagnostics and therapeutics to address unmet needs in the field of cancer. The company's approach involves leveraging cutting-edge technologies such as artificial intelligence, machine learning, and computational biology to identify novel biomarkers and therapeutic targets. By utilizing these advanced technologies, Anixa aims to enhance early cancer detection, improve treatment outcomes, and ultimately save lives. Through strategic partnerships and collaborations, Anixa Biosciences Inc is dedicated to transforming the way cancer is diagnosed and treated.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Anixa Biosciences.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Anixa Biosciences.

Το AlleAktien Qualitätsscore για το Anixa Biosciences είναι 1/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Anixa Biosciences.

Τα κέρδη για τον Anixa Biosciences δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Anixa Biosciences Inc is a biotechnology company specializing in the development of products for the diagnosis, treatment, and prevention of cancer. The company is headquartered in San Jose, California, USA and was founded in 1982. Anixa Biosciences specializes in four different business areas: diagnostics, therapeutics, vaccines, and oncology. In the diagnostics field, the company offers tests for various types of cancer. These diagnostic tests are based on proprietary technologies such as liquid biopsy technology and the CchekTM prostate cancer tumor DNA test. In the therapeutics field, Anixa Biosciences has developed various cellular therapies focused on immunotherapy. This involves directing immune cells against cancer cells to destroy them. The company is also working on the development of RNAi therapeutics that can suppress the expression of certain genes in cancer cells. In the vaccines field, Anixa Biosciences is developing vaccines against various types of cancer. The main focus is on the development of cancer vaccines that stimulate the immune system to recognize and destroy cancer cells. In the oncology field, Anixa Biosciences offers products and services that support researchers, clinics, and pharmaceutical companies focused on the discovery of new cancer therapies. The products and services of Anixa Biosciences are based on proprietary technologies such as the NexGenTM platform, which allows for rapid and accurate cancer diagnosis. This technology also utilizes machine learning and artificial intelligence to further improve cancer diagnosis. Anixa Biosciences has partnerships with various players in the healthcare and biotechnology industries to market its innovative products and services. The company also utilizes patented technologies to protect the exclusivity of its products and services. Overall, Anixa Biosciences' business model enables the development and marketing of innovative products and services that contribute to the diagnosis, treatment, and prevention of cancer. The company specializes in various sectors and utilizes proprietary technologies to strengthen its market position.

Η Anixa Biosciences καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Anixa Biosciences αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Anixa Biosciences είναι US03528H1095.

Το WKN της Anixa Biosciences είναι A2N6ZF.

Ο τίκερ της Anixa Biosciences είναι ANIX.

Κατά τους τελευταίους 12 μήνες η Anixa Biosciences κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Anixa Biosciences προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Anixa Biosciences ανέρχεται σήμερα στο .

Anixa Biosciences πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Anixa Biosciences πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Anixa Biosciences ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Anixa Biosciences από την 9/9/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 9/9/2024.

Η τελευταία μερίσματος έγινε στις 9/9/2024.

Το έτος 2023, η Anixa Biosciences διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Anixa Biosciences καταβάλλονται σε USD.